Introduction
The analysis of DNA copy number changes throughout the whole genome started with the introduction of comparative genomic hybridization (CGH), first described in 1992 by Kallioniemi et al. [1] . This elegant technique was based on the competitive hybridization of two pools of fluorescent-labeled probes, one made up of whole-genome DNA of a test and another of a control sample, to a metaphase preparation of normal chromosomes. Along each chromosome, the fluorescent intensity of the test DNA was quantified and compared with the control intensity, resulting in 'relative copy number karyotypes. ' It appeared to be very difficult to reproduce the method in laboratories not specialized in chromosome techniques. Only after the publication of an article reviewing all steps in great detail did CGH become more widely applied [2] , especially in cancer genetics. The possibility of using DNA obtained from formalin-fixed and paraffin-embedded (FFPE) samples opened up the way for retrospective studies of tumors with clinical follow-up data, enabling the identification of genetic changes related to tumor progression, invasion and metastasis [3] .
The resolution of what is now called classical CGH is limited to a chromosomal band, approximately 5-10 Mb. This was overcome by the introduction of array comparative genomic hybridization (aCGH) in 1997 [4, 5] . The method is essentially the same, but now an array of genomic DNA clones or oligonucleotides serves as hybridization target, rather than metaphase chromosomes. The resolution of aCGH is now defined by the choice and/or the number of DNA clones and later oligonucleotides, and another advantage is that it does not require karyotyping. At the present moment, aCGH using oligonucleotide or single nucleotide polymorphism (SNP) arrays is most widely applied [6] .
Multiple ligation-dependent probe amplification (MLPA), developed and first published in 2002 by Schouten et al. [7] , is an alternative DNA copy number analysis technique, especially when specific genes or chromosomal regions are already known to be of interest. MLPA requires only 20 ng of DNA, enough to allow the simultaneous quantification of up to 50 different targets, which may be as small as 50 nucleotides. Another advantage of MLPA lies in its reproducibility and specificity, allowing application in a routine diagnostic setting while remaining time-and cost-efficient.
One increasingly important application is genomic profiling of FFPE samples. Across the world, large collections of FFPE samples with clinical follow-up exist. However, the DNA from FFPE samples shows varying levels of degradation depending largely on the length and the method of fixation, and on age of the specimen. This chapter aims to describe in detail the methods of oligonucleotide aCGH, SNP aCGH and MLPA, with special attention for the use of DNA obtained from FFPE samples. These techniques have primarily been used in cancer research; however, they are also suitable for the analysis of DNA copy number aberrations in human genetic disorders.
Methods and approaches

Oligonucleotide aCGH
The first whole-genome microarray contained 2400 large-insert genomic clones, primarily bacterial artificial chromosomes (BACs) [8] . With the total human genome covering about 3000 Mb the resolution of this array is on average close to 1 Mb, which is about one order of magnitude higher than that obtained with classical CGH [1] . For a full coverage resolution, about 30 000 BACs have been arrayed [9] , increasing the resolution by another order of magnitude. However, producing such large numbers of BACs for aCGH is expensive and time consuming; and due to the large size of the BACs, the resolution limits for BAC aCGH resolution were reached.
Several laboratories used cDNA arrays, initially designed for expression profiling, as an alternative for measuring chromosomal copy number changes [10] . Even though this approach has certainly yielded valuable information, it cannot compete with the oligonucleotide platforms in terms of its maximal achievable resolution. Oligonucleotides allow a sheer infinite resolution, great flexibility and are cost effective [6] . They also enable the generation of microarrays for any organism for which the genome has been sequenced. Using the same oligonucleotide array for CGH and expression profiling allows direct comparison of mRNA expression and DNA copy number ratios. In addition, oligonucleotide arrays are being used, designed and accepted for expression profiling, and thus are widely available. 1  1  1  1  1  2  2  3  3  3  4  4  5  5  6  6  7  7  8  8  9  10  10  11  11  12  12  13  14  14  15  16  16  17  17  18  19  19  20  21  22  23   18 3776  66 8696  1859258  3616362  5642180  6997887  9011848  12340071  17364859  19690142  27616824  32808653  35704118  44583203  47030516  56562219  58478821  60460403  61676803  62405946  63772113  64569894  65187600  65856155  66872960  67682447  70823832  72790077  74811170  77013704  82843999  91728159  95650832   1 0285 5054  1 0785 0817  1 1128 9521  1 1455 1391  1 1760 3000  1 1867 5448  1 2149 1464  1 2425 9836  1 2664 Commercial oligonucleotide aCGH platforms include Illumina (60 mer), Operon (70 mer), Affymetrix (25 mer), Agilent (60 mer) and NimbleGen (45-85 bp), the latter with now up to 2.1 million oligonucleotides on the array [11] . The quality of the oligonucleotide aCGH platforms is rapidly improving, with single oligonucleotides rapidly reaching the sensitivity of single BAC clones. Not all of the current oligonucleotide aCGH platforms can make a definite call for loss or gain using a single oligonucleotide, but in some cases three to five adjacent oligonucleotides are necessary for a reliable call [6, 11] . Moreover, owing to improvements in protocols, DNA isolated from FFPE tumor samples now works comparable to DNA from fresh material (Protocols 1.1-1.4) on long (>50 bp) oligonucleotide arrays (see Figure 1 .1).
The principle of oligonucleotide aCGH is the same as all aCGH variants: Labeled tumor DNA (Protocol 1.5) competes with differentially labeled normal DNA for hybridizing to an array of oligonucleotides (Protocol 1.6). Using a specialized scanner and digital image processing software, the ratio of the two is measured per spot on the array. Deviations from the normal ratio of 1.0, or the log 2 ratio of 0.0, represent a copy number aberration of genetic material in the tumor. The final result is DNA copy number information for all the oligonucleotides on the array, which can be ordered according to the chromosomal localization (Protocol 1.7). Graphics may represent all spots at once or only those belonging to one chromosome (see Figure 1 .1). The sensitivity of CGH depends on the purity of the tumor sample and of the quality of the DNA obtained.
The oligonucleotide aCGH protocol presented provides a highly sensitive and reproducible platform applicable to DNA isolated from both fresh and FFPE tissue. We do not present protocols on the preparation of the array slides, since these can be purchased commercially. • Phenol solution (e.g. Sigma-Aldrich, P-4557)
• Chloroform
• Isopropanol
• Phenol/chloroform: 50% (v/v) phenol, 50% (v) chloroform
• TE: 10 mM Tris-HCl, pH 8.0, 1 mM EDTA
• Ethanol (70% (v/v) and 100% (v/v), both ice-cold)
• Sodium acetate (3 M, pH 5.2).
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Method
1 To a 1.5 ml microcentrifuge tube add:
• 0.5-1 cm 3 of tissue;
• 600 μl of EDTA/nuclei lysis solution;
• 17.5 μl of proteinase K.
2 Incubate overnight at 55
• C with gentle shaking, or vortex the sample several times during the incubation.
3 Add 3 μl of RNase solution to the nuclear lysate and mix the sample by inverting the tube two to five times.
4 Incubate the mixture for 15-30 min at 37
• C.
5 Add 200 μl of protein precipitation solution to the sample and vortex vigorously. Chill the sample on ice for 10 min.
6 Centrifuge at 20 000g for 15 min at room temperature to pellet the precipitated protein.
7 Carefully transfer the supernatant containing the DNA to a fresh 1.5 ml microcentrifuge tube.
8 Add 600 μl of isopropanol (at room temperature).
9 Mix the solution by gently inverting until the white thread-like strands of DNA form a visible mass.
10 Centrifuge at 20 000g for 1 min at room temperature. The DNA will be visible as a small white pellet. Carefully aspirate supernatant by decanting the liquid. Air dry until no ethanol is visible.
11 Add 200 μl of TE to resuspend the DNA.
12 Pellet 2 ml of PLG light by centrifuging at 12 000-16 000g for 20-30 s at room temperature.
13 Add the 200 μl of DNA-containing TE to the 2 ml PLG light tube, followed by 200 μl of phenol-chloroform.
14 Mix the organic and the aqueous phases thoroughly by inversion. a 15 Centrifuge at 12 000-16 000g for 5 min at room temperature to separate the phases. Transfer the upper layer/supernatant to a new 1.5 ml microcentrifuge tube.
16 Add 200 μl of chloroform directly to the above new 1.5 ml microcentrifuge tube.
17 Mix thoroughly by inversion. a 18 Centrifuge at 12 000-16 000g for 5 min at room temperature to separate the phases.
8 Add 1 ml of PBS, mixing a few times by vortexing.
9 Centrifuge at 14 000g for 5 min at room temperature and discard the supernatant.
10 Repeat steps 8 and 9 once.
11 Incubate with 1 ml of 1 M NaSCN overnight at 38-40
• C, mixing a few times by vortexing.
12 Centrifuge at 14 000g for 5 min at room temperature and discard the supernatant.
13 Wash the pellet three times with 1 ml of PBS as in steps 11 and 12.
14 Add 200 μl of Buffer ATL (QIAamp kit) and 20 μl of proteinase K, mixing a few times by vortexing. 24 Add 500 μl of Buffer AW2 (QIAamp kit) to the column.
25 Centrifuge at 14 000g for 3 min at room temperature and discard the flow through.
26 Transfer the column to a fresh microcentrifuge tube (with a lid). 4 Add 100 μl of diluted Picogreen reagent to each diluted DNA sample and mix by pipetting up and down.
5 Centrifuge the microtitre plate at 250g for 1 min to remove possible bubbles.
6 Read in a plate reader (excitation 485 nm, emission 538 nm).
7 Calculate concentrations from the standard curve using the plate reader software package.
Notes
d Avoid excess exposure to light since the dye is light sensitive.
e For quantitation of DNA from FFPE tissue for SNP arrays, the use of Picogreen gives more reliable estimates than measurement of A 260 nm using a spectrophotometer [12] .
PROTOCOL 1.4 DNA Quality Control PCR Equipment and reagents
• Primer stocks (100 μM):
-RS2032018 (150 bp)
• primer 1: 5'-GTGTCTCCCTTCCCACTCAA-3'
• primer 2: 5'-AGCCCACCTACCTTGGAAAG-3' -AP000555 (PRKM1, 255 bp)
• primer 3: 5'-TGGCTGATCTATGTCCCTGA-3'
• primer 4: 5'-GCTCAGTTGTTTTGTGGGTAAG-3' -AC008575 (APC, 511 bp)
• primer 5 GCTCAGACACCCAAAAGTCC
• primer 6: CATTCCCATTGTCATTTTCC
• Polymerase chain reactions (PCRs) reaction buffer II without MgCl 2 (Applera)
• Amplitaq gold DNA polymerase (5 units/μl Applera).
Method
1 Prepare a primer working solution mix containing 20 pm/μl of primers 1 and 2, and 10 pm/μl for primers 3-6. f 2 Prepare a 10 μl reaction by mixing the following:
• 0.25 μl of primer mix 3 Thermocycle as follows:
• 96
• C, 10 min
• 72
• C, 5 min.
Notes
f The multiplex PCR amplifies three amplicons, one each of of 150 bp, 255 bp and 511 bp. This method is comparable to the van Beers method [38] . g Use 10 ng of genomic DNA prepared from freshly frozen tissue as a control.
h If the DNA concentration (see Protocol 1.9) is higher than 5 ng/μl it can be diluted in water.
i The 150 and 255 bp amplicons have to amplify for a DNA template considered to be suitable for aCGH.
PROTOCOL 1.5 Labeling of DNA for Oligonucleotide aCGH Equipment and reagents
• BioPrime DNA labeling system (Invitrogen, 18094-011), containing:
-2.5× random primers solution -Klenow fragment of DNA polymerase I (40 U/μl); keep on ice at all times, or preferably use a −20
• C labcooler when taking in and out of the freezer.
• Cy3-labeled dCTP (e.g. Amersham Biosciences/Perkin Elmer)
• Cy5-labeled dCTP (e.g. Amersham Biosciences/Perkin Elmer)
• ProbeQuant G-50 Micro Columns (Amersham Biosciences)
• dNTP mixture; for 200 μl mix: 5 Prepare a Probe-Quant G-50 column for removal of uncoupled dye material as follows:
• resuspend the resin in the column by vortexing;
• loosen the cap one-fourth turn and snap off the bottom closure;
• place the column in a 1.5 ml microcentrifuge tube and centrifuge at 735g for 1 min. l 6 Place the column into a fresh 1.5 ml tube and slowly apply 50 μl of the sample to the top center of the resin, being careful not to disturb the resin bed.
7 Centrifuge the column at 735g for 2 min. The purified sample is collected at the bottom of the support tube.
8 Discard the column and store the purified and labeled sample m in the dark until use on the same day, or alternatively store at −20
• C for a maximum of 10 days. l Start the timer and microcentrifuge simultaneously to ensure that the total centrifugation time does not exceed 1 min. m It is not necessary to exactly quantify the labeled DNA or the degree of Cy5/Cy3-dCTP incorporation, because in the data analysis a normalization of the Cy5/Cy3 channels takes place.
Notes
PROTOCOL 1.6 Hybridization Equipment and reagents
• Blocking solution: n 0.1 M Tris, 50 mM ethanolamine, pH 9.0: dissolve 6.055 g of Trizma base and 7.88 g of Trizma-HCl in 900 ml of water. Add 3 ml of ethanolamine (Sigma-Aldrich Chemie B.V. Zwijndrecht, Netherlands) and mix thoroughly. Adjust the pH to 9.0 using 6 N HCl. Adjust the final volume to 1 l with water.
• 20× SSC, pH 7.0 (e.g. Sigma) and dilutions in water (0.2×, 0.1× and 0.01× SSC).
• 20% (w/v) SDS solution: for preparation of 100 ml, dissolve 20 g of sodium dodecyl sulfate in 90 ml of water. Adjust the final volume to 100 ml.
• Wash solution: 4× SSC, 0.1% (w/v) SDS: 200 ml of 20× SSC, 10 ml of 10% (w/v) SDS, adjust the final volume to 1 l with water.
• Human Cot-1 DNA, 1 μg/μl (e.g. Invitrogen).
• Yeast tRNA, 100 μg/μl (e.g. Invitrogen).
• Master mix -14.3% (w/v) dextran sulfate, 50% (v/v) formamide, 2.9× SSC, pH 7.0: Combine 1 g of dextran sulfate (USB), 3.5 ml of redistilled formamide (Invitrogen; store at −20 • C), 2.5 ml of water and 1 ml of 20× SSC. Gently shake for several hours to dissolve the dextran sulfate and store aliquoted at −20 • C.
• Washing buffer: 50% (v/v) formamide, 2× SSC, pH 7.0.
• PN buffer: 0.1 M Na 2 HPO 4 /NaH 2 PO 4 , pH 8.0, 0.1% (v/v) Igepal CA630 (e.g. Sigma).
• GeneTAC/HybArray12 hybstation (Genomic Solutions/Perkin Elmer). 12 Denature the hybridization solution at 73
Method
• C for 10 min, and incubate at 37
• C for 60 min to allow the Cot-1 DNA to block repetitive sequences. 14 Assemble up to six hybridization units (two slides per unit): insert rubber O-rings in the covers and put the slides on the black bottom plate. Make sure the slides are in the proper orientation with the printed side up.
15 Introduce the unit into the hybstation, press unit down with one hand while tightening the screw with the other.
16 Insert plugs into the sample ports and the waste tubes into the corresponding wash bottles.
17 On the touch screen subsequently press: start a run, from floppy, CGH.hyb, load, the positions of the slides you want to use, start, continue (the hybstation starts to warm up the slides).
18 When the hybstation is ready (visible on screen by indication of the module you have to start) apply hyb mix:
(a) press Probe to add the hyb mix for the selected slide 19 Take slides out after 38 h and put them in 0.01× SSC.
20 Place each slide in a 50 ml tube and centrifuge at 200g for 3 min to dry.
21 Immediately scan slides in a microarray scanner.
22 Cleaning the hybstation: u 23 Reassemble all used hybridization units with dummy slides and introduce them into the hybstation.
24 Insert plugs into all sample ports and place all tubes in a bottle of water.
25 On the touch screen subsequently press: maintenance, Machine Cleaning Cycle, the positions of the slides you used, continue.
26 When cleaning is finished, take out the hybridization units, rinse with water (never use ethanol) especially the sample port and dry the unit with the air pistol. 
PROTOCOL 1.7 Scanning and Creation of a Copy Number Profile Equipment and reagents
• High-resolution laser scanner, or imager equipped to detect Cy3 and Cy5 dyes, including software to acquire images (e.g. Microarray Scanner G2505B, Agilent Technologies)
• Feature-extraction software (e.g. Bluefuse 3.2 (BF), BlueGnome Ltd, UK)
• Gene array list (GAL-file, or equivalent) -created by the microarray printer software using the oligonucleotide plate content lists provided by the supplier of the oligo library
• Position list: a file, containing the relative positions of the oligonucleotides in the genome under investigation, provided by the supplier of the oligo library, or created by mapping the oligonucleotide sequences onto the genome concerned
• Software which calculates ratios, links the genomic position of the oligonucleotide to the experimental ratios and draws a profile (e.g. Microsoft Excel, or dedicated software such as BF).
Method
1 Allow scanner lasers to warm up for 5 min before starting.
2 Scan the microarray at 10 μm scanning resolution according to the manufacturer's protocol.
3 Store scans from both channels as separate TIFF images 4 Perform automated spot finding, using the information from the GAL-file to position the array grid over each image.
5 Perform automated spot exclusion. v 6 Perform automated linking of the spot ratios to the genomic positions of the corresponding oligonucleotides (using the information from the position file).
7 Perform global mode normalization. w 8 Draw the genomic profile (automated in BF): order normalized ratios by chromosomal mapping and display in a graph.
x Notes v We suggest excluding spots that have a 'confidence value' lower than 0.1, or a 'quality flag' lower than 1, which will further diminish outliers. These confidence values are calculated in a proprietary manner by the BF feature extraction software. w Avoid block normalization (normalization per printed block of spots on the array slide, which can be performed by either median, or intensity-dependent lowess), because this may compress the profile. Mode normalization is used to set the 'normal' level and is preferred over mean or median normalization, as it is more accurate since it ignores the ratios generated by gains, amplifications and deletions. Block normalization is sometimes used to suppress noise, although its suitability may depend on the type of sample analyzed; that is, for samples showing few aberrations, block normalization may help to suppress noise, but is not recommended for samples with multiple chromosomal aberrations (e.g. tumor samples).
x For more sophisticated analysis procedures and to 'call' the actual gains, losses and amplifications, we recommend the use of more dedicated software, such as the freeware CGH call [14] .
SNP aCGH
The recently developed high-density SNP microarrays were originally developed for high-throughput genotyping for linkage analysis and association studies. These arrays have additionally proven useful to measure both genomic copy-number variations and loss of heterozygosity (LOH); that is, SNP aCGH. The ability of SNP aCGH, unlike conventional CGH, to detect copy-neutral genetic anomalies offers the benefit of detecting copy-neutral LOH [15] . Moreover, the combination of copy number abnormalities and LOH status with the parental origin of the aberrant allele can possibly be associated with the predisposition to hereditary cancer. Successful use of SNP aCGH has been reported for several cancers, such as breast, colorectal and lung cancer [16] [17] [18] [19] . While the current high-density SNP arrays can interrogate more than a million SNPs, these arrays cannot (yet) be used reliably with DNA from FFPE tissue. This is due to the fragmented nature of the DNA isolated from FFPE tissue. For this purpose, current arrays are restricted to 6000−10 000 features. Different methodologies and types of commercially available SNP arrays exist. These consist of either locus-specific arrays of oligonucleotides (Genechips) or of arrays with universal capture oligonucleotide on beads that are randomly assembled on arrays and subsequently decoded (Beadarrays). Genechips can detect up to 250 000 SNPs on a single chip. For each SNP, a set of locus-specific oligonucleotides is synthesized on the array. The sample is prepared according to a whole-genome sampling assay [20] . After restriction enzyme digestion of high molecular weight genomic DNA and ligation of a common adaptor, the DNA is amplified in a single-primer PCR and hybridized to a locus-specific array [21] . For Infinium arrays, genomic DNA is whole-genome amplified, subsequently fragmented, and denatured DNA is hybridized to a locus-specific array. An allele-specific primer extension assay on the array is followed by staining and scanning of the arrays using standard immunohistochemical detection methods. Currently these arrays can detect over a million SNPs on a single array [22] . Goldengate genotyping makes use of a multiplex mixture of probes for 96, 384, 768 or 1536 SNPs per array [23] . For each SNP, a combination of allele-specific and locus-specific primers is annealed to the SNP locus, the primers are tailed with common forward and reverse primers and a complementary universal capture probe to the locus-specific primer. Subsequent allele-specific primer-extension, followed by ligation, generates an allele-specific artificial PCR template. This template is then PCR-amplified and labeled. After hybridization to an array of universal-capture probes, the array is scanned in two colors, representing the two alleles of an SNP. Molecular-inversion probe (MIP) genotyping utilizes a pool of circularizable locus-specific probes with a multiplexing degree of over 10 000 SNPs per array. The 5' and 3' ends of each probe anneal upstream and downstream of the SNP. The 1 bp gap is filled; subsequent ligation seals the nick and generates a circular probe. Restriction digestion then releases the circularized probe and the resultant product is PCR-amplified using common primers [24] . The four nucleotide reactions are labeled in different colors and pooled. Subsequently, the pool is hybridized to an array of universal-capture probes and the four colors are read out in a scanner. Whereas the high-density Genechip and Infinium arrays are designed for use with high-quality genomic DNA, both the Goldengate and the MIP assay can be used to detect LOH and copy number changes in FFPE tissue [25, 26] .
SNP aCGH collects both intensity and allelic information from a sample. To extract profiles of LOH and copy number abnormalities, different methods and algorithms have been reported [13, [27] [28] [29] [30] . For the interpretation of LOH and copy number abnormalities, specifically for the Goldengate assay, a limited or no method was available. Therefore, to interpret the Beadarray data an R-package BeadArraySNP was developed. The package deals with the normalization of the allele-specific signal intensities and the representation of the copy number and LOH profiles [25] .
Here we describe the use of the GoldenGate assay and Beadarrays to generate high-resolution copy number profiles and LOH using DNA isolated from FFPE tissue (Protocol 1.8). We do not present Illumina protocols, since this is a commercial platform. The most recent version of the protocol (user card) can be obtained through www .illumina.com.
PROTOCOL 1.8 Data Analysis of Illumina SNP Beadarray Experiments Equipment and reagents
• Illumina BeadScan software for genotyping and the Bioconductor (www.bioconductor.org) BeadarraySNP package [25] • Quantile smoothing software [31] .
Method y
1 Perform an Illumina GoldenGate TM assay, y according to the protocol supplied by Illumina, using 1 μg of activated DNA (isolated from FFPE tissue) dissolved in 60-100 μl of RS1 buffer.
2 Scan z the Illumina arrays using the Illumina BeadScan software, aa creating (by default) the following types of files for each of the samples on the array:
• locs: locations of beads on the array
• idat: summarized intensity information (binary format)
• XML: scanner settings.
3 Adapt the Settings.xml bb within the beadstudio directory in order to produce the additional file types. <SavePerBeadFiles>true<\SavePerBeadFiles> <SaveEIFFiles>false<\SaveEIFFiles> <SaveTextFiles>true<\SaveTextFiles> <CompressImages>true<\CompressImages> <ExcludeOutliers>true<\ExcludeOutliers> <IncludeXY>true<\IncludeXY> 4 Perform the genotyping of the scanned images using the GenCall software, cc producing the following types of files for each experiment. • *-OPA_LocusByDNA_*DNA_Report.csv: summary of allele frequencies for each sample
• *-OPA_LocusByDNA_*Final.csv: genotyping and quality scores (each probe and sample appear on a separate row)
• *-OPA_LocusByDNA_*Locus_Report.csv: quality index summaries for all probes.
6 Begin copy number analysis ee by defining the samples in a sample sheet. ff Calculate the copy number values for all the samples in the experiment using the function standardNormalization().
7 Plot the raw and smoothed copy number data using the Quantile smoothing software. gg cc Illumina provides two software packages that can perform genotyping on the scanned images. Gencall was the original application for genotyping and was followed by BeadStudio, which is an integrated package for performing all kinds of data analysis for Illumina arrays. The algorithm for genotyping differs between the packages. We prefer to use the results of GenCall as the input for copy number analysis. If genotyping is performed with the Illumina Gencall software then the csv files are needed to obtain copy number values. dd Beadstudio produces a report file with a specifiable number of result fields. For the copy number analysis the following fields are needed: GC Score Allele1 -AB Allele2 -AB GT Score X Raw Y Raw. The report file will contain the chosen values for each sample and probe. ee This calculation consists of three stages: normalizeBetweenAlleles.SNP() Performs quantile normalization between both colors of a sample. This is allowed because the frequencies of both alleles throughout a sample are nearly identical in practice. This action also neutralizes any dye bias. normalizeWithinArrays.SNP() scales each sample using the median of the high-quality heterozygous SNPs as the normalization factor. Genomic regions that show copy number alterations are likely to show LOH, or are harder to genotype leading to a decrease quality score of the call. normalizeLoci.SNP() scales each probe using the normal samples in the experiment, assuming that these samples are diploid, and have a copy number of two. ff This can be the file produced by the Illumina genotyping software, but it is useful to include more information on the individual samples here; for example, experimental groups, normal/tumor tissue. The format for these data is explained in detail in the help pages for the package. The data quality should be checked. The overview of average intensities for both channels as laid out on the physical device has proved helpful to detect technical anomalies. For the GoldenGate assay both channels should have an average intensity above 1250. gg Various plots of raw or smoothed copy number data can be obtained using the Quantile smoothing software, such as: smoothed intensities from all chromosomes for a number of samples, all samples in an experiment indicating regions of gain, loss and LOH, for individual chromosomes, or a BAC-array-like plot for each sample in an experiment. hh A gain is called where the 25th percentile line exceeds the 2N line and a loss is called where the 75th percentile is below the diploid line.
Multiple ligation-dependent probe amplification (MLPA)
The MLPA technique was first described by Schouten et al. [7] in 2002 and has become a rapidly growing technique used in the detection of aberrations in genes related to various diseases. MLPA is a multiplex technique for determining copy numbers of genomic DNA sequences [32] and promoter methylation status [33] , as well as mRNA profiling [34] . While genomic profiling is becoming increasingly important in both the research and diagnostic setting, routine detection methods for exon deletions and duplications are still lacking.
To date, MLPA technology has shown its applicability in the research setting through several studies. These include detection of trisomies [35] , Duchene and Becker muscular dystrophy [36] , centrifugal muscular dystrophy and also detection of deletions and duplications of one or more exons of the BRCA1 [37] and the MLH1 /MSH2 genes [32] . However, the protocols described in this chapter are robust and specific enough to be used as a routine diagnostic assay. MLPA is easy to perform and relatively cheap. Up to 96 samples can be handled simultaneously and results can be obtained within 24 h. The required apparatus for MLPA (a thermocycler and sequencing type electrophoresis equipment) is present in most molecular biology laboratories. Probe target sequences are small (50-70 nucleotides), meaning that MLPA can be applied to partially degraded DNA, such as FFPE tissue DNA, or free fetal DNA obtained from maternal plasma. MLPA reactions are more sensitive to contaminants, often present in DNA samples extracted from FFPE tissues, than ordinary PCRs. Developing new MLPA probe mixes is complicated, expensive and time consuming. Each probe requires the design and preparation of a phage M13 clone, the purification of its single stranded DNA and digestion with expensive restriction endonucleases. For research purposes, it is possible to design a small number of completely synthetic probes, resulting in amplification products with lengths varying between 100 and 130 nucleotides.
MLPA is an approach based on the PCR technique, and is sufficiently sensitive, reproducible and sequence-specific to allow the relative quantification of up to 50 different targets simultaneously. In MLPA, probes and not sample nucleic acids are subject to amplification and quantification. MLPA probes consist of one short synthetic oligonucleotide and one M13-derived, long probe oligonucleotide, which hybridize to adjacent sites of the target sequence. The short probe contains a target-specific sequence (21-30 nucleotides) and a 19 nucleotide sequence at the 5 end which is identical to the sequence of a labeled PCR primer. The long MLPA probe contains 24-43 nucleotides of target-specific sequence at the 5 phosphorylated end, a 36 nucleotide sequence that contains the complement of an unlabeled PCR primer at the 3 end, and a stuffer sequence of variable length in between. This variable-length fragment gives each complete probe the necessary size difference for detection and quantification using capillary gel electrophoresis [7] . Hybridized probe oligonucleotides are then ligated by a specific ligase enzyme, but only when both probes are stably hybridized to adjacent sites of the target sequence, permitting subsequent amplification (Protocol 1.9; see Figure 1. 3).
MLPA probes are identified after capillary separation by size, using a selected size standard for the size calling procedure (Protocol 1.10). The relative MLPA probe signals (fluorescent units) reflect the relative copy number of the target sequence. An indication of the DNA input in the performed MLPA reaction may be obtained by examining the dosage quotient (DQ) control fragments, fragments whose lengths always co-vary and which are present in all MLPA kits. The signals of these fragments will be prominent if the amount of sample DNA is very low. By contrast, the fifth control band of 92 nucleotides is ligation dependent and should have a signal similar to most other MLPA amplification products. Visual inspection of the peak pattern of a patient sample superimposed over a peak pattern of a reference run can be used to analyze few sample numbers. Analyzing a larger sample series, more complex diseases and MLPA runs performed with miscellaneous sample types and quality require exportation of the peak signals and reliable normalization methods (Protocol 1.11).
To date, more than 150 MLPA applications are available, and this number is still growing rapidly. MLPA kits for the most common hereditary genetic disorders are already available, such as: Down's syndrome (see Figure 1.4) , breast (BRCA1 ) [37] and colon cancer [32] (MSH2 and MLH1 ), Duchenne [36] , cystic fibrosis, centrifugal muscular atrophy, sickle cell anemia and Marfan syndrome, to name but a few. However, future MLPA kits will focus more on the detection of aberrations of genes playing roles in tumorigenesis, apoptosis, angiogenesis and pharmacogenetics. -Hybridization program
• 98
• C, 5 min
• 25
• C, hold
• 95
• C, 1 min
• 60
• C, hold.
-Ligation program
• 54
• C, 15 min
-PCR program
• C, hold Vortex briefly.
8 Prepare a probe master mix by combining (per DNA sample) 1.5 μl of probe mix and 1.5 μl of MLPA buffer.
9 When the thermocycler reaches 25
• C, add 3 μl of probe master mix to each DNA sample.
Mix well by pipetting up and down. 14 Continue the program on the thermocycler to advance to the 54 • C hold step.
15 When the samples are at 54
• C, add 32 μl of the ligase buffer plus Ligase-65 mix to each reaction tube and mix well by pipetting up and down.
16 Continue the program on the thermocycler to advance to the next step (15 min incubation at 54 • C, followed by 5 min at 98
• C, and holding at 4
• C). Store pp the ligation products at 4
• C for up to 1 week.
17 In a pre-PCR location, remove 10× SALSA PCR buffer, SALSA PCR-primers and SALSA enzyme dilution buffer from the freezer and allow to thaw. Vortex briefly.
18 Label new tubes for PCR with the same sample initials and probe set numbers used for the hybridization and ligation reactions.PCR products can be stored at 4
• C for at least 1 week. As the fluorescent labels used are light sensitive, the PCR products should be stored in a dark box, or wrapped in aluminum foil. • Deionized formamide (ABI, 4311320)
• Labelled size standard (ROX-500 ABI GeneScan 401734; TAMRA-500 ABI GeneScan 401733).
rr Method ss,tt ABI-310:
1 Following the PCR reactions, for each reaction mix:
• 0.75 μl of the PCR reaction
• 0.75 μl of water
• 0.5 μl of ROX-labeled internal size standard
• 12 μl of deionized formamide.
2 Mix by pipetting, incubate at 94 • C for 2 min and cool on ice.
3 Start the fragment separation software using the following settings: • filter: C.
ABI-3100 and ABI 3100 Avant:
• 8.5 μl of deionized formamide
• 1-3 μl of the PCR reaction.
2 Pipette this mixture into the injection plate.
3 Seal the injection plate with plate sealing film and incubate at 92
• C for 2 min, and hold at 4
• C for 5 min.
4 Start the fragment separation software using the following settings:
• run temperature: 60 • C
• capillary fill volume: 184 steps 
ABI-3700: ss,tt
• 2 μl of the PCR reaction
• 0.2 μl of ROX-labeled internal size standard
• 10 μl of deionized formamide.
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• C for 2 min and hold at 4
• sample volume: 2.5 μl Notes uu MLPA product fragment lists should have the following plot settings -Genescan (ABI): dye, time, peak length, peak height, peak area; Genemapper (ABI): peak dye, sample file name, peak height, peak area. vv The protocol describes the creation of copy number ratio from MLPA product fragment lists using MLPA-DAT. ww Reference runs are usually MLPA runs performed on normal human DNA samples within the same experiment as the samples. Multiple reference runs are recommended for probability calculation of the sample ratios found. Mean or median normalization are only recommended with larger sample numbers investigating syndromes with a low prevalence. xx The DNA concentration, DNA ligation check and signal count are performed automatically.
yy Quantification is fully automated in MLPA-DAT and includes removal of individual run variance. The principle of normalization is twofold. First, all peak areas are converted into relative peak areas by dividing each by the sum of all peak areas. Second, a normalization factor is calculated from the ratio between the relative peak areas of all control probes of a sample and a reference DNA. Normalization settings may depend on the MLPA kit and type of sample analysed; for samples showing few aberrations, normalization can be done using all probes, but for samples with multiple chromosomal aberrations, such as tumor samples, it is recommended to use the control probes only. Control probe normalization sets the internal run normalization factor on a number of MLPA-probes known to remain constant in the expected sample types, while the amount of run variance is either determined on these probes only, or on all probes. zz This is automatic in MLPA-DAT.
aaa A deletion of one copy of a probe target sequence will usually be apparent by a reduction in relative peak area for that probe amplification product of 35-55%. A gain in copy number from two to three copies/diploid genome will usually be apparent by an increase in relative peak area between 30 and 55%.
Troubleshooting
• Low concentration of DNA isolated from FFPE tissue: When a low yield of DNA is expected from FFPE tissue, glycogen can be added as a co-precipitant prior to ethanol precipitation. This has no noticeable effect on aCGH results.
• DNA contaminants in MLPA: MLPA reactions are more sensitive to contaminants than ordinary PCR reactions. DNA samples extracted from FFPE tissues often contain contaminants. Small remnants of phenol may act as PCR inhibitors, giving amplification products with lower average peak areas. Reducing the amount of DNA used will therefore sometimes have a beneficial effect. Normalization of these DNA samples should be performed against DNA extracted from reference DNA of the same source of tissue.
• Low MLPA peak areas: The quantity of a probe amplification product is primarily determined by the target sequence of the probe. MLPA probes located in guanine-and cytosine-rich areas often have difficulty reaching their target due to incomplete denaturation of the DNA. Better results may be obtained with these MLPA mixes by increasing the length of the initial denaturation step to 98
• C for 10 min. The probe signals are further influenced by the quality of the probe oligonucleotides and the amount of KCl and polymerase present during the PCR reaction. The polymerase activity may influence the relative signal strength of some probes; therefore, mixing the master mix well by pipetting up and down is strongly advised. It is also possible that the DNA input was too low. This is likely if the average signal of the four DQ (DNA quality) fragments is less than one-third of the ligation-dependent peak signal.
